Charts

10 Feb, 2024
09 Feb, 2024

News

21 Feb, 2024
BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference at the Boston Marriott Copley Place in Boston, Massachuse
02 Feb, 2024
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
16 Jan, 2024
The most oversold stocks in the health care presents an opportunity to buy into undervalued companies. The RSI is a momentum ...
11 Jan, 2024
Shares of Richardson Electronics, Ltd. (NASDAQ: RELL) fell sharply in today’s pre-market trading after the company posted ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the hottest news this morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors
10 Jan, 2024
VYN201 demonstrated positive effect on key biomarkers relevant to vitiligo Data supports VYN201’s rapid onset of action and previously announced positive clinical resultsProgram is on track for Phase 2b initiation in Q2 BRIDGEWATER, N.J., Jan. 10, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, to
03 Jan, 2024
BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the appointment of Christine Borowski, Ph.D., to its board of directors, effective as of January 1, 2024. “We are pleased to welcome Dr. Borowski to our Board of Directors during this important time in the
13 Nov, 2023
12:50
FinancialContent
VYNE Therapeutics (NASDAQ:VYNE) reported its Q3 earnings results on Monday, November 13, 2023 at 07:45 AM. Here's what investors need to ...
Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025 Phase 2b preparatory activities progressing for VYN201 in nonsegmental vitiligo following positive Phase 1b results On track for VYN202 IND submission by year-end 2023, with plans to begin Phase 1a trial in Q1 2024 BRIDGEWATER, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage bi
07 Nov, 2023
Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE’s clinical development plans Program to feature KOL presentation covering unmet need and current treatment landscape in vitiligo BRIDGEWATER, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today an
01 Nov, 2023
Transformative capital raise to fund VYNE’s BET inhibitor programs through the end of 2025BRIDGEWATER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the closing of its previously announced private placement financing (the “PIPE”). In the PIPE, VYNE received aggrega
30 Oct, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 500 points on Monday. The Dow traded ...
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the ...
Gainers Miromatrix Medical (NASDAQ:MIRO) shares increased by 217.2% to $3.3 during Monday's regular session. The current volume of 2.9 ...
Earlier today,VYNE Therapeutics Inc(NASDAQ: VYNE) released new preclinical data showing the positive effect of its VYN202 in ...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday. The Dow traded up ...
VyneTherapeutics Inc. (NASDAQ: VYNE) shares are trading higher Monday after the company announced a private placement of $88 ...
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 250 points on Monday. Following the market opening ...
Gainers Miromatrix Medical (NASDAQ:MIRO) stock rose 223.1% to $3.36 during Monday's pre-market session. The company's market cap stands ...
Treatment with VYN202 resulted in significant inhibition of key inflammatory biomarkers and substantial resolution of the signs and symptoms of psoriasis and rheumatoid arthritisFollowing completion of recent financing, VYNE expects to initiate a Phase 1a SAD/MAD clinical trial in Q1 2024, followed by Phase 1b trials in moderate-to-severe plaque psoriasis and in moderate-to-severe adult-onset rheumatoid arthritis in the second half of 2024Preclinical data and clinical programs to be discussed at
Transaction provides $88 million to fund VYNE’s clinical development programs for VYN201 and VYN202 through the end of 2025BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that the Company has signed a securities purchase agreement with certain healthcare
Clinical proof-of-concept achieved with statistically significant dose dependent reduction in F-VASI score from baseline for the VYN201 1.0% and 2.0% cohorts compared to the 0.5% cohort VYN201 was generally well-tolerated with no clinically relevant treatment emergent adverse events across all dose cohorts Clinical response and rapid onset of action suggest VYN201 has the potential to be the category leader in the treatment of nonsegmental vitiligo VYN201 is expected to advance into a Phase 2b c
18 Oct, 2023
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Extended Market ETF (VXF), we found that the implied analyst target price for the ETF based upon its underlying holdings is $174.78 per unit.
26 Sep, 2023
Gainers Galecto (NASDAQ:GLTO) stock increased by 40.3% to $0.81 during Tuesday's after-market session. At the close, Galecto's trading ...
06 Sep, 2023
BRIDGEWATER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. Management will a
14 Aug, 2023
Anticipate announcing preliminary Phase 1b safety and efficacy data for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in Q3 2023 IND-enabling studies for VYN202, a potential best-in-class oral small molecule BD2-selective BET inhibitor, are ongoing in anticipation of indication selection in Q4 2023 and initiating a Phase 1 trial in Q1 2024 BRIDGEWATER, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceuti
18 May, 2023
BRIDGEWATER, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that members of management will attend the Biotechnology Innovation Organization (BIO) International Convention, taking place June 5-8, 2023 at the Boston Convention & Exhibition Center in Boston,
12 May, 2023
Gainers ARS Pharmaceuticals (NASDAQ:SPRY) shares increased by 79.4% to $8.11 during Friday's regular session. ARS Pharmaceuticals's ...
Gainers GSI Technology, Inc. (NASDAQ: GSIT) shares surged 108% to $3.4207. GSI Technology is expected to announce financial ...
11 May, 2023
21:35
FinancialContent
VYNE Therapeutics (NASDAQ:VYNE) reported its Q1 earnings results on Thursday, May 11, 2023 at 04:00 PM. Here's what investors need to ...
Anticipate topline 16-week data for all three cohorts from the Phase 1b trial for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in the third quarter of 2023 IND-enabling studies for VYN202, a potential best-in-class oral small molecule BD2-selective BET inhibitor, are ongoing in anticipation of an IND filing by year-end 2023 BRIDGEWATER, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focu
10 May, 2023
Gainers CTI BioPharma (NASDAQ:CTIC) shares rose 85.2% to $8.93 during Wednesday's regular session. As of 13:30 EST, CTI BioPharma's ...
01 May, 2023
Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development VYN202 has demonstrated a potent anti-inflammatory and anti-fibrotic effect in multiple validated preclinical models of autoimmune disease IND-enabling studies are ongoing in anticipation of an IND filing by year-end BRIDGEWATER, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company devel
19 Apr, 2023
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Wednesday. The Dow traded down 0.23% ...
Gainers China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) gained 85.2% to $1.25 after the company announced the termination of its ...
VYNE Therapeutics Inc(NASDAQ: VYNE) announced new preclinical data showing the effect of its novel pan-BET inhibitor, VYN201, ...
U.S. stocks traded lower this morning, with the Dow Jones dropping over 100 points on Wednesday. Following the market opening ...
Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 34.2% to $0.81 during Wednesday's pre-market session. The market value of their ...
VYN201 at the 0.5 mg/ml and 1 mg/ml doses demonstrated statistically significant reductions in lung fibrosis and hydroxyproline levels compared to placeboReduction in lung fibrosis from VYN201 treatment resulted in significant improvements in blood oxygen saturation and functional lung volumeData further supports potential broad utility of VYN201 as a potent locally-administered anti-inflammatory and anti-fibrotic molecule BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics I
16 Apr, 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips You have to be patient when investing in pharma stocks. But sometimes the risk and the wait aren't worth the rewards. The post 7 Sorry Pharma Stocks to Sell in April Before It’s Too Late appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It
30 Mar, 2023
VYNE Therapeutics Inc(NASDAQ: VYNE) announced first-in-humanpharmacokinetic and hematology datafrom its Phase 1a ...
No quantifiable VYN201 plasma concentrations above the assay lower limit of quantification supports “soft” drug approach for topical pan-BD BET inhibitor All hematological parameters, including platelet counts, were within normal ranges, a finding which has not previously been observed with systemically administered pan-BD BET inhibitors Topline Phase 1b results in patients with nonsegmental vitiligo expected in mid-2023 BRIDGEWATER, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc
23 Mar, 2023
Gainers ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) shares rose 82.8% to $2.98 in pre-market trading. ZyVersa Therapeutics recently ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Thursday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It
22 Mar, 2023
BRIDGEWATER, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammation D
09 Mar, 2023
First vitiligo patients being treated with pan-BD BET inhibitor, VYN201, for up to 16 weeks in Phase 1b clinical trial Anticipate topline Phase 1b data in mid-2023 BRIDGEWATER, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the four
28 Feb, 2023
BRIDGEWATER, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that it received a notification letter (the "Notification Letter on Compliance") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on February 28, 2023, indicating
08 Feb, 2023
Gainers 23andMe Holding (NASDAQ:ME) shares moved upwards by 12.3% to $2.83 during Wednesday's after-market session. Trading volume for ...
13 Jan, 2023
Gainers Jasper Therapeutics (NASDAQ:JSPR) stock rose 32.1% to $2.18 during Friday's pre-market session. The market value of their ...
10 Jan, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 100 points on Tuesday. The Dow traded up ...
Gainers Sotera Health Company (NASDAQ: SHC) shares jumped 92% to $16.59 after the company announced its subsidiaries have reached ...
Gainers Sotera Health (NASDAQ:SHC) stock moved upwards by 86.9% to $16.15 during Tuesday's regular session. The current volume of 38.4 ...
VYNE Therapeutics Inc(NASDAQ: VYNE) announced that the first vitiligo patienthad been dosedin a Phase 1a/b trial of ...
Gainers Prenetics Global (NASDAQ:PRE) stock rose 74.7% to $3.25 during Tuesday's pre-market session. The market value of their ...
Gainers VYNE Therapeutics Inc. (NASDAQ: VYNE) rose 82.2% to $0.35 in pre-market trading after the company said first vitiligo ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the day with an overview of the biggest pre-market stock movers traders need to know about for Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.
09 Jan, 2023
Gainers VYNE Therapeutics (NASDAQ:VYNE) shares rose 87.0% to $0.36 during Monday's after-market session. At the close, VYNE ...
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company ...
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) rose 140.2% to $28.30 in pre-market trading after AstraZeneca announced plans to buy ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.
06 Jan, 2023
Gainers Lucira Health (NASDAQ:LHDX) shares rose 29.5% to $0.51 during Friday's after-market session. Lucira Health's trading volume hit ...
05 Jan, 2023
Gainers Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares surged 179.3% to $2.4585 after the company announced that it has ...
Gainers Bellerophon Therapeutics (NASDAQ:BLPH) stock rose 171.1% to $2.48 during Thursday's regular session. As of 12:30 EST, this ...
22 Sep, 2022
On Thursday, 1076 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with ...
09 Sep, 2022
VYNE Therapeutics (NASDAQ:VYNE) brought in sales totaling $126 thousand during Q2 according to data provided by Benzinga Pro. However, ...
12 Aug, 2022
VYNE Therapeutics (NASDAQ:VYNE) reported its Q2 earnings results on Friday, August 12, 2022 at 07:00 AM. Here's what ...

Related Articles